A number of other brokerages also recently weighed in on PETQ. Guggenheim began coverage on shares of PetIQ in a report on Thursday, May 23rd. They set a buy rating and a $35.00 target price on the stock. Raymond James lowered their target price on shares of PetIQ from $42.00 to $39.00 and set an outperform rating on the stock in a report on Monday, March 4th. Zacks Investment Research upgraded shares of PetIQ from a hold rating to a buy rating and set a $33.00 target price on the stock in a report on Friday, May 17th. Finally, ValuEngine downgraded shares of PetIQ from a buy rating to a hold rating in a report on Saturday, March 9th. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. PetIQ presently has an average rating of Buy and a consensus target price of $40.71.
Shares of PETQ opened at $30.10 on Monday. The firm has a market capitalization of $859.82 million, a P/E ratio of 24.08, a price-to-earnings-growth ratio of 1.54 and a beta of 1.88. PetIQ has a 1-year low of $21.29 and a 1-year high of $43.93. The stock’s fifty day moving average price is $28.82. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.51 and a current ratio of 2.89.
PetIQ (NASDAQ:PETQ) last issued its earnings results on Wednesday, May 8th. The company reported $0.27 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.08 by $0.19. The business had revenue of $148.44 million for the quarter, compared to the consensus estimate of $139.03 million. PetIQ had a net margin of 0.51% and a return on equity of 9.47%. On average, analysts predict that PetIQ will post 0.8 earnings per share for the current year.
In related news, Director James Nathan Clarke acquired 31,031 shares of the firm’s stock in a transaction on Wednesday, May 15th. The shares were purchased at an average cost of $28.12 per share, for a total transaction of $872,591.72. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Will Santana sold 20,000 shares of the company’s stock in a transaction on Wednesday, April 24th. The shares were sold at an average price of $30.77, for a total transaction of $615,400.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 100,291 shares of company stock worth $2,914,491. Corporate insiders own 23.79% of the company’s stock.
Large investors have recently added to or reduced their stakes in the business. Manchester Capital Management LLC acquired a new position in shares of PetIQ in the first quarter valued at $30,000. Bank of Montreal Can increased its holdings in shares of PetIQ by 2,007.8% in the fourth quarter. Bank of Montreal Can now owns 1,623 shares of the company’s stock valued at $38,000 after purchasing an additional 1,546 shares during the last quarter. Citigroup Inc. increased its holdings in shares of PetIQ by 43.5% in the fourth quarter. Citigroup Inc. now owns 1,827 shares of the company’s stock valued at $43,000 after purchasing an additional 554 shares during the last quarter. FNY Investment Advisers LLC acquired a new position in shares of PetIQ in the first quarter valued at $56,000. Finally, Legal & General Group Plc increased its holdings in shares of PetIQ by 42.6% in the fourth quarter. Legal & General Group Plc now owns 2,451 shares of the company’s stock valued at $58,000 after purchasing an additional 732 shares during the last quarter. Hedge funds and other institutional investors own 91.87% of the company’s stock.
PetIQ Company Profile
PetIQ, Inc operates as a pet health and wellness company. It operates through two segments, Products and Services. It manufactures and distributes veterinarian services and veterinarian-grade pet products, including prescription (Rx) medications, over-the-counter (OTC) flea and tick preventatives, and health and wellness products for dogs and cats.
Featured Article: Does a trade war provide a risk to the global economy?
Receive News & Ratings for PetIQ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetIQ and related companies with MarketBeat.com's FREE daily email newsletter.